TD Cowen raised the firm’s price target on DarioHealth (DRIO) to $11 from 60c and keeps a Hold rating on the shares. The company updated its model following Q3 results which showed its revenue weakness continuing but noting its strong pipeline could lead to a recovery in 2026.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DRIO:
- DarioHealth price target lowered to $16 at Stifel after reverse stock split
- DarioHealth Reports Q3 2025 Financial Results
- DarioHealth’s Earnings Call: Optimism Amid Revenue Shift
- DarioHealth’s Mixed Financial Outlook: Hold Rating Amidst Revenue Challenges and Future Growth Prospects
- DarioHealth reports Q3 EPS ($2.96), consensus ($2.42)